Intelligence Feed event · Equity · 2026-08-28

    Biohaven partners with SK Biopharmaceuticals in $795M licensing deal

    Question

    Biohaven partners with SK Biopharmaceuticals in $795M licensing deal

    Direct answer

    Biohaven announced a worldwide licensing collaboration with SK Biopharmaceuticals worth up to $795 million. The deal centers on Biohaven's Kv7 ion channel platform, led by drug candidate opakalim targeting focal epilepsy. In addition to the licensing transaction, Biohaven and Yale University won a $4 million judgment. The combined cash inflows bolster capital reserves for advancing clinical programs without requiring immediate equity capital market issuance.

    Original publisher
    Market Ontology
    Evidence through
    2026-08-28
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Biohaven partners with SK Biopharmaceuticals in $795M licensing deal”, revision 1, evidence through 2026-08-28. https://marketontology.com/market-events/2026-08-28/biohaven-partners-with-sk-biopharmaceuticals-in-795m-licensing-deal-bfac40

    EQUITY
    Biohaven partners with SK Biopharmaceuticals in $795M licensing deal
    Biohaven announced a worldwide licensing collaboration with SK Biopharmaceuticals worth up to $795 million. The deal centers on Biohaven's Kv7 ion channel platform, led by drug candidate opakalim targeting focal epilepsy. In addition to the licensing transaction, Biohaven and Yale University won a $4 million judgment. The combined cash inflows bolster capital reserves for advancing clinical programs without requiring immediate equity capital market issuance.
    BHVN
    Impact
    73
    AUG 28
    SIG
    85%
    BHVN
    Biohaven partners with SK Biopharmaceuticals in $795M licensing deal
    Biohaven announced a worldwide licensing collaboration with SK Biopharmaceuticals worth up to $795 million. The deal centers on Biohaven's Kv7 ion channel platform, led by drug candidate opakalim targeting focal epilepsy. In addition to the licensing transaction, Biohaven and Yale University won a $4 million judgment. The combined cash inflows bolster capital reserves for advancing clinical programs without requiring immediate equity capital market issuance.
    → Biohaven monetizes pipeline IP through $795 million in milestone and licensing potential, reducing near-term dilutive equity financing needs.
    Impact
    Biohaven announced a worldwide licensing collaboration with SK Biopharmaceuticals worth up to $795 million. The deal centers on Biohaven's Kv7 ion channel platform, led by drug candidate opakalim targeting focal epilepsy. In addition to the licensing transaction, Biohaven and Yale University won a $4 million judgment. The combined cash inflows bolster capital reserves for advancing clinical programs without requiring immediate equity capital market issuance.
    Affected
    BHVN
    Transmission
    Biohaven monetizes pipeline IP through $795 million in milestone and licensing potential, reducing near-term dilutive equity financing needs.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    BHVNnon-dilutive milestone cash inflow from $795M licensing partnershipUp1-5dSource reports Biohaven licensing deal with SK Biopharmaceuticals worth up to $795 million for opakalim.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month